Sevelamer Induced Necrotizing Ileitis: A Case Report
DOI:
https://doi.org/10.71749/pkj.99Keywords:
Renal Insufficiency, Chronic/drug therapy, Ileitis/etiology, Sevelamer/adverse effectsAbstract
The prevalence of chronic kidney disease (CKD) has surged globally over the past two decades. Sevelamer, a non‑calcium phosphate binder, has gained popularity due to its relatively good safety profile for treating hyperphosphatemia in CKD patients. However, recent reports have identified a novel side effect of sevelamer: deposition in the gastrointestinal (GI) mucosa, leading to injury. Symptoms range from nonspecific abdominal discomfort to severe complications such as ulceration and gangrene. Demonstration of characteristic sevelamer crystals in biopsies is diagnostic. To date, 40 reports of sevelamer‑induced GI complications exist in the literature. An elderly male suffering from end‑stage renal disease presented with sub‑acute intestinal obstruction. He failed to respond to initial conservative measures and upon exploration was found to have necrotising ileitis due to sevelamer‑induced inflammation with mass formation. In CKD patients presenting with abdominal pain, clinicians should maintain a high index of suspicion for Sevelamer‑induced intestinal injury.
Downloads
References
Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease: a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. doi:10.1371/journal.pone.0158765
Di Rienzo G, Crafa P, Delsante M, et al. Histopathological lesions of the gastrointestinal tract associated with the use of polystyrene sulfonate and sevelamer: a meta-analysis. Pathologica. 2024;116:216-221.
Rosenberg M. Overview of the management of chronic kidney disease in adults. In: Connor RF, ed. UpToDate. Waltham, MA: Wolters Kluwer; [updated 2023]. Accessed January 10, 2025. https://www.uptodate.com/contents/overview-of-the-management-of-chronic-kidney-disease-in-adults
Chan S, Au K, Francis RS, et al. Phosphate binders in patients with chronic kidney disease. Aust Prescr. 2017;40(1):9-14. doi:10.18773/austprescr.2017.002
Madan P, Bhayana S, Chandra P, Hughes JI. Lower gastrointestinal bleeding: association with sevelamer use. World J Gastroenterol. 2008;14(16):2615. doi:10.3748/wjg.14.2615
Swanson BJ, Limketkai BN, Liu TC, et al. Sevelamer crystals in the gastrointestinal tract: a new entity associated with mucosal injury. Am J Surg Pathol. 2013;37(11):1686-1693. doi:10.1097/PAS.0b013e3182999d8d
Bathobakae L, Phuu P, Yasin S, et al. Sevelamer-induced gastrointestinal mucosal injury: a critical review for clinicians. J Community Hosp Intern Med Perspect. 2024;14(6):58-65. doi:10.55729/2000-9666.1424
Tonelli M, Wiebe N, Culleton B, et al; for the Alberta Kidney Disease Network. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant. 2007;22(10):2856-2866. doi:10.1093/ndt/gfm421
Navaneethan SD, Palmer SC, Vecchio M, et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev. 2011;(2):CD006023. doi:10.1002/14651858.CD006023.pub2
Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268-1277. doi:10.1016/S0140-6736(13)60897-1
Patel L, Bernard LM, Elder GJ. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2016;11(2):232-244. doi:10.2215/CJN.06800615
Palmer SC, Gardner S, Tonelli M, et al. Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. Am J Kidney Dis. 2016;68(5):691-702. doi:10.1053/j.ajkd.2016.05.015
Lioufas NM, Pascoe EM, Hawley CM, et al. Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol. 2022;33(1):59-76. doi:10.1681/ASN.2021040554
Downloads
Published
Issue
Section
License
Copyright (c) 2025 B M Nandakumar, Bharati V Hiremath, N Rahul
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
